CDC, Pfizer deny blood clot risks, but studies suggest otherwise.
After administering nearly 100 million doses of Pfizer’s vaccine, the CDC reported there hasn’t been a single related case of a blood clot forming in the brain as of April 12.
Utilizing a search criteria that included reports of blood clots associated with blood clotting disorders, VAERS yielded a total of 2,808 reports for all three vaccines from Dec. 14, 2020, through April 30. Of the 2,808 cases reported, there were 1,043 reports of blood clotting disorders attributed to Pfizer.
As The Defender reported in April, scientists warned U.S regulatory officials as far back as December 2020 that Pfizer and Moderna COVID vaccines pose similar blood clot risks as the Johnson & Johnson.
A study published in February in the Journal of Hematology examined thrombocytopenia following Pfizer and Moderna vaccination in response to the death of a 56-year-old Florida physician — the first identified patient who died from a brain hemorrhage 15 days after receiving Pfizer’s vaccine.
Researchers examined 20 case reports of patients with immune thrombocytopenia (ITP) following vaccination, including 17 without pre‐existing thrombocytopenia using data from the CDC, U.S Food and Drug Administration (FDA), U.S. Department of Health and Human Services, VAERS, published reports and communications with patients and treating providers.
After analyzing data, researchers could not exclude the possibility that the Pfizer and Moderna vaccines had the potential to trigger ITP and recommended additional surveillance to determine the incidence of thrombocytopenia post vaccination.
A study released by Oxford University found the number of people who developed cerebral venous sinus thrombosis (CVST) blood clots after COVID vaccines was about the same for Pfizer, Moderna and AstraZeneca — the vaccine predominately used in other parts of the world, and which EU regulators linked to blood clots.
According to the Oxford study, 4 in 1 million people experienced CVST during the two weeks following vaccination with the Pfizer or Moderna vaccine, versus 5 in 1 million people with AstraZeneca.
The Association of American Physicians and Surgeons further identified 37 cases of people who developed a rare platelet disorder after receiving the Pfizer or Moderna shot, and informed the FDA that mRNA vaccines, through spike proteins, may have “the potential to cause microvascular injury [inflammation and small blood clots called microthrombi] to the brain, heart, liver and kidneys in ways that were not assessed in the safety trials.” The FDA never responded.
On Dec. 8, 2020, before any COVID vaccines received Emergency Use Authorization in the U.S., Harvard-trained physician J. Patrick Whelan, M.D., Ph.D., wrote the FDA about the potential for vaccines designed to create immunity to the SARS-CoV-2 spike protein “to cause microvascular injury and blood clots throughout the body including the brain, heart, liver and kidneys in ways that were not assessed in the safety trials.”
Whelan acknowledged the vaccines’ potential to quickly arrest the spread of the virus — assuming vaccines prove to actually prevent transmission, which also was not assessed in the clinical trials. But he cautioned “it would be vastly worse if hundreds of millions of people were to suffer long-lasting or even permanent damage to their brain or heart microvasculature as a result of failing to appreciate in the short-term an unintended effect of full-length spike protein-based vaccines on other organs.”
Last month, Johnson & Johnson reached out to Pfizer, Moderna and AstraZeneca to join a study on the potential of the COVID vaccines’ to cause blood clots. Officials at AstraZeneca said they were interested, but Pfizer and Moderna declined to participate in the study.